Structure and function of matrix metalloproteinases and TIMPs.

[1]  C. Tsai,et al.  Purification and Characterization , 2006 .

[2]  S. Ye.  Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. , 2006, Cardiovascular research.

[3]  Motoharu Seiki,et al.  MT1‐MMP: A potent modifier of pericellular microenvironment , 2006, Journal of cellular physiology.

[4]  松村 紳一郎.  Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice , 2006 .

[5]  Jason L. Johnson,et al.  Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  K. Brew,et al.  Reactive Site Mutations in Tissue Inhibitor of Metalloproteinase-3 Disrupt Inhibition of Matrix Metalloproteinases but Not Tumor Necrosis Factor-α-converting Enzyme* , 2005, Journal of Biological Chemistry.

[7]  J. Couchman,et al.  Palmitoylation at Cys574 is essential for MT1‐MMP to promote cell migration , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  D. Szczesna‐Cordary,et al.  Degradation of Myosin Light Chain in Isolated Rat Hearts Subjected to Ischemia-Reperfusion Injury: A New Intracellular Target for Matrix Metalloproteinase-2 , 2005, Circulation.

[9]  Zena Werb,et al.  Galectin-3 is a downstream regulator of matrix metalloproteinase-9 function during endochondral bone formation. , 2005, Molecular biology of the cell.

[10]  E. Fleck,et al.  Furin-Like Proprotein Convertases Are Central Regulators of the Membrane Type Matrix Metalloproteinase–Pro-Matrix Metalloproteinase-2 Proteolytic Cascade in Atherosclerosis , 2005, Circulation.

[11]  Tomoyuki Shirai,et al.  MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. , 2005, Cancer cell.

[12]  G. A. Limb,et al.  Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. , 2005, The American journal of pathology.

[13]  G. Murphy,et al.  Total Conversion of Tissue Inhibitor of Metalloproteinase (TIMP) for Specific Metalloproteinase Targeting , 2005, Journal of Biological Chemistry.

[14]  W. Bode,et al.  X-ray Structure of Human proMMP-1 , 2005, Journal of Biological Chemistry.

[15]  F. Spinale,et al.  Trafficking of the Membrane Type-1 Matrix Metalloproteinase in Ischemia and Reperfusion: Relation to Interstitial Membrane Type-1 Matrix Metalloproteinase Activity , 2005, Circulation.

[16]  K. Maskos.  Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. , 2005, Biochimie.

[17]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[18]  T. Itoh,et al.  Matrix Metalloproteinase-9 in Macrophages Induces Thymic Neovascularization following Thymocyte Apoptosis , 2005, The Journal of Immunology.

[19]  A. Newby,et al.  Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. , 2005, Physiological reviews.

[20]  K. Ikari,et al.  Matrix metalloproteinase 28/epilysin expression in cartilage from patients with rheumatoid arthritis and osteoarthritis: comment on the article by Kevorkian et al. , 2004, Arthritis and rheumatism.

[21]  W. Stetler-Stevenson,et al.  Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. , 2004, The Biochemical journal.

[22]  G. Murphy,et al.  Delineating the Molecular Basis of the Inactivity of Tissue Inhibitor of Metalloproteinase-2 against Tumor Necrosis Factor-α-converting Enzyme* , 2004, Journal of Biological Chemistry.

[23]  R. Khokha,et al.  TIMP-3 Deficiency Leads to Dilated Cardiomyopathy , 2004, Circulation.

[24]  B. Fingleton,et al.  Abnormal TNF activity in Timp3−/− mice leads to chronic hepatic inflammation and failure of liver regeneration , 2004, Nature Genetics.

[25]  A. Thathiah,et al.  MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. , 2004, The Biochemical journal.

[26]  D. Dinakarpandian,et al.  Collagenase unwinds triple‐helical collagen prior to peptide bond hydrolysis , 2004, The EMBO journal.

[27]  A. Strongin,et al.  β-Catenin regulates the gene of MMP-26, a novel matrix metalloproteinase expressed both in carcinomas and normal epithelial cells , 2004 .

[28]  G. Murphy,et al.  Threonine 98, the Pivotal Residue of Tissue Inhibitor of Metalloproteinases (TIMP)-1 in Metalloproteinase Recognition* , 2004, Journal of Biological Chemistry.

[29]  M. Sung,et al.  Matrix metalloproteinase‐2 (MMP‐2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP‐ribose) polymerase (PARP) in vitro , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  E. Portiansky,et al.  Myocardial hypertrophy of normotensive Wistar-Kyoto rats. , 2004, American journal of physiology. Heart and circulatory physiology.

[31]  J. Keski‐Oja,et al.  Co-recycling of MT1-MMP and MT3-MMP through the Trans-Golgi Network , 2004, Journal of Biological Chemistry.

[32]  R. Mecham,et al.  Oxidative Cross-linking of Tryptophan to Glycine Restrains Matrix Metalloproteinase Activity , 2004, Journal of Biological Chemistry.

[33]  K. Yano,et al.  Matrix Metalloproteinase-7 Facilitates Insulin-Like Growth Factor Bioavailability through Its Proteinase Activity on Insulin-Like Growth Factor Binding Protein 3 , 2004, Cancer Research.

[34]  Carlos Fernandez-Patron,et al.  Agonist-Induced Activation of Matrix Metalloproteinase-7 Promotes Vasoconstriction Through the Epidermal Growth Factor–Receptor Pathway , 2004, Circulation research.

[35]  宮本 心一.  Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein-3 , 2004 .

[36]  A. Strongin,et al.  Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. , 2004, The international journal of biochemistry & cell biology.

[37]  A. Parker,et al.  Expression profiling of metalloproteinases and their inhibitors in cartilage. , 2004, Arthritis and rheumatism.

[38]  M. C. Ovejero,et al.  Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. , 2004, Bone.

[39]  M. Karjalainen‐Lindsberg,et al.  Matrix Metalloproteinase-21 Is Expressed Epithelially During Development and in Cancer and Is Up-Regulated by Transforming Growth Factor-β1 in Keratinocytes , 2003, Laboratory Investigation.

[40]  R. Sedláček,et al.  Matrix metalloproteinase-19 expression in normal and diseased skin: dysregulation by epidermal proliferation. , 2003, The Journal of investigative dermatology.

[41]  R. Sedláček,et al.  Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. , 2003, Molecular biology of the cell.

[42]  C. Overall,et al.  HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration , 2003, Nature Neuroscience.

[43]  Gillian Murphy,et al.  Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface , 2003, Journal of Cell Science.

[44]  A. Takeshita,et al.  Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. , 2003, American journal of physiology. Heart and circulatory physiology.

[45]  W. Kisiel,et al.  Human tissue factor pathway inhibitor-2 does not bind or inhibit activated matrix metalloproteinase-1. , 2003, Biochimica et biophysica acta.

[46]  A. Strongin,et al.  The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. , 2003, The Biochemical journal.

[47]  F. Gomis-Rüth,et al.  Structural aspects of the metzincin clan of metalloendopeptidases , 2003, Molecular biotechnology.

[48]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[49]  R. Nagle,et al.  Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. , 2003, Cancer research.

[50]  K. Miyazaki,et al.  Identification of a Region of β-Amyloid Precursor Protein Essential for Its Gelatinase A Inhibitory Activity* , 2003, The Journal of Biological Chemistry.

[51]  K. Brew,et al.  Protein Engineering of the Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Inhibitory Domain , 2003, The Journal of Biological Chemistry.

[52]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[53]  J. Dyck,et al.  Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury , 2002, Circulation.

[54]  Timothy C Greiner,et al.  Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. , 2002, The Journal of clinical investigation.

[55]  Jiankun Cui,et al.  S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death , 2002, Science.

[56]  T. Pourmotabbed,et al.  Unexpected Crucial Role of Residue 272 in Substrate Specificity of Fibroblast Collagenase* , 2002, The Journal of Biological Chemistry.

[57]  B. Mari,et al.  Alternative Splicing and Promoter Usage Generates an Intracellular Stromelysin 3 Isoform Directly Translated as an Active Matrix Metalloproteinase* , 2002, The Journal of Biological Chemistry.

[58]  J. Keski‐Oja,et al.  Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. , 2002, The Journal of investigative dermatology.

[59]  W. Bao,et al.  Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. , 2002, Cardiovascular research.

[60]  Ekaterina Morgunova,et al.  Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  R. Visse,et al.  Matrix Metalloproteinases Regulation and Dysregulation in the Failing Heart , 2002 .

[62]  Hiroshi Ohno,et al.  Cytoplasmic tail–dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity , 2001, The Journal of cell biology.

[63]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[64]  W. English,et al.  Characterization of the Role of the “MT-loop” , 2001, The Journal of Biological Chemistry.

[65]  E. Kerkelä,et al.  Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. , 2001, Bone.

[66]  J. Fata,et al.  Accelerated apoptosis in the Timp-3-deficient mammary gland. , 2001, The Journal of clinical investigation.

[67]  T. Mak,et al.  Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). , 2001, The Journal of clinical investigation.

[68]  R. Williamson,et al.  Tyrosine 36 Plays a Critical Role in the Interaction of the AB Loop of Tissue Inhibitor of Metalloproteinases-2 with Matrix Metalloproteinase-14* , 2001, The Journal of Biological Chemistry.

[69]  G. Murphy,et al.  Specific collagenolysis by gelatinase A, MMP‐2, is determined by the hemopexin domain and not the fibronectin‐like domain , 2001, FEBS letters.

[70]  M. Llinás,et al.  Gelatin-binding Region of Human Matrix Metalloproteinase-2 , 2001, The Journal of Biological Chemistry.

[71]  P. Libby,et al.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. , 2001, The Journal of clinical investigation.

[72]  C. Overall,et al.  Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. , 2001, Cancer research.

[73]  D. Pei,et al.  Cysteine Array Matrix Metalloproteinase (CA-MMP)/MMP-23 Is a Type II Transmembrane Matrix Metalloproteinase Regulated by a Single Cleavage for Both Secretion and Activation* , 2000, The Journal of Biological Chemistry.

[74]  C. López-Otín,et al.  Biochemical Characterization of the Catalytic Domain of Human Matrix Metalloproteinase 19 , 2000, The Journal of Biological Chemistry.

[75]  X. Puente,et al.  Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2* , 2000, The Journal of Biological Chemistry.

[76]  B. Fingleton,et al.  Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. , 2000, The Journal of clinical investigation.

[77]  J. Mott,et al.  Post-translational Proteolytic Processing of Procollagen C-terminal Proteinase Enhancer Releases a Metalloproteinase Inhibitor* , 2000, The Journal of Biological Chemistry.

[78]  J. Woessner,et al.  Matrix metalloproteinases and TIMPs , 2000 .

[79]  M. Radomski,et al.  Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. , 1999, Circulation research.

[80]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[81]  J. Ward,et al.  MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover , 1999, Cell.

[82]  P. Wingfield,et al.  Biophysical and Functional Characterization of Full-length, Recombinant Human Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Produced in Escherichia coli , 1999, The Journal of Biological Chemistry.

[83]  G. Schneider,et al.  Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.

[84]  K. Miyazaki,et al.  Reactive Site-modified Tissue Inhibitor of Metalloproteinases-2 Inhibits the Cell-mediated Activation of Progelatinase A* , 1999, The Journal of Biological Chemistry.

[85]  K. Brew,et al.  Residue 2 of TIMP-1 Is a Major Determinant of Affinity and Specificity for Matrix Metalloproteinases but Effects of Substitutions Do Not Correlate with Those of the Corresponding P1′ Residue of Substrate* , 1999, The Journal of Biological Chemistry.

[86]  A. Fincham,et al.  Characterization of Recombinant Pig Enamelysin Activity and Cleavage of Recombinant Pig and Mouse Amelogenins , 1999, Journal of dental research.

[87]  C. López-Otín,et al.  Cloning and Characterization of Human MMP-23, a New Matrix Metalloproteinase Predominantly Expressed in Reproductive Tissues and Lacking Conserved Domains in Other Family Members* , 1999, The Journal of Biological Chemistry.

[88]  J. Calvete,et al.  Crystal structure of the complex formed by the membrane type 1‐matrix metalloproteinase with the tissue inhibitor of metalloproteinases‐2, the soluble progelatinase A receptor , 1998, The EMBO journal.

[89]  M. Kurkinen,et al.  Cloning and Characterization of a Novel Matrix Metalloproteinase (MMP), CMMP, from Chicken Embryo Fibroblasts , 1998, The Journal of Biological Chemistry.

[90]  U. Krawinkel,et al.  Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. , 1998, Immunobiology.

[91]  P. Shah,et al.  Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. , 1997, Circulation.

[92]  R. Huber,et al.  Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 , 1997, Nature.

[93]  M. Kurkinen,et al.  A Novel Matrix Metalloproteinase Gene (XMMP) Encoding Vitronectin-like Motifs Is Transiently Expressed in Xenopus laevis Early Embryo Development* , 1997, The Journal of Biological Chemistry.

[94]  B. Smith,et al.  Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP‐8) to stability and collagenolytic activity by alanine scanning mutagenesis , 1997, FEBS letters.

[95]  Y. Okada,et al.  Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules* , 1997, The Journal of Biological Chemistry.

[96]  T. Ley,et al.  Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Qi-Zhuang Ye,et al.  The Structural Basis for the Elastolytic Activity of the 92-kDa and 72-kDa Gelatinases , 1996, The Journal of Biological Chemistry.

[98]  J. Springer,et al.  Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme , 1995, Protein science : a publication of the Protein Society.

[99]  B. Hazleman,et al.  Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller. , 1995, Structure.

[100]  Stephen J. Weiss,et al.  Furin-dependent intracellular activation of the human stromelysin-3 zymogen , 1995, Nature.

[101]  James P. Quigley,et al.  Matrix Metalloproteinase-2 Is an Interstitial Collagenase , 1995, The Journal of Biological Chemistry.

[102]  J. Quigley,et al.  Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. , 1995, The Journal of biological chemistry.

[103]  S. Weiss,et al.  Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. , 1994, The Journal of biological chemistry.

[104]  M. Cockett,et al.  Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. , 1994, The Journal of biological chemistry.

[105]  R. Huber,et al.  The X‐ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. , 1994, The EMBO journal.

[106]  N. Borkakoti,et al.  Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor , 1994, Nature Structural Biology.

[107]  M. Walid Qoronfleh,et al.  Structure of human neutrophil collagenase reveals large S1′ specificity pocket , 1994, Nature Structural Biology.

[108]  A M Hassell,et al.  Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. , 1994, Science.

[109]  W. Bode,et al.  Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc‐binding environments (HEXXHXXGXXH and Met‐turn) and topologies and should be grouped into a common family, the ‘metzincins’ , 1993, FEBS letters.

[110]  P. Chambon,et al.  The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. , 1993, The Journal of biological chemistry.

[111]  H. Sengeløv,et al.  Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. , 1993, The Journal of biological chemistry.

[112]  R. Hembry,et al.  Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain. , 1991, Journal of cell science.

[113]  D. Strickland,et al.  Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. , 1990, The Journal of biological chemistry.

[114]  K. Suzuki,et al.  Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. , 1990, Biochemistry.

[115]  I. Clark,et al.  Fragments of human fibroblast collagenase. Purification and characterization. , 1989, The Biochemical journal.

[116]  S. Weiss,et al.  Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[117]  A. Eisen,et al.  Human skin fibroblast collagenase: interaction with substrate and inhibitor. , 1985, Collagen and related research.

[118]  D. Garcia-Dorado,et al.  Cardiovascular Research , 1966 .

[119]  T. Sadowskia,et al.  Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces epithelial cell migration , 2022 .